

**NEPHRO CARE INDIA LIMITED**

CIN: L85100WB2014PLC202429

Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake,  
Bidhan Nagar,Sai Complex, North 24 Parganas, Kolkata – 700106.

Web: <https://www.nephrocareindia.com/>

[cs@nephrocareindia.com](mailto:cs@nephrocareindia.com) | Mobile No. 9004551166

**Date: 27/05/2026**

**To,**  
**The Manager - Listing Department**  
**National Stock Exchange of India Limited,**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051

**Symbol - NEPHROCARE**

**Sub: Outcome of Board Meeting dated 27<sup>th</sup> May 2026**

**Ref: Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Madam,

Pursuant to the provision of Regulation 30, 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”) this is to inform you that the Board of Directors of the Company at its meeting duly held today Wednesday, 27<sup>th</sup> May, 2026, (commenced at 04:00 P.M and concluded at 04:45 P.M) at Corporate Office of the Company situated at EFC Limited, 12th Floor, Millennium City, Tower 2, DN Block, DN-62, Salt Lake, Sector -5, Bidhan Nagar, Kolkata – 700091 inter alia, approved and adopted the following;

- 1) The Audited Standalone & Consolidated Financial Results for the half year and year ended 31<sup>st</sup> March 2026 along with the Statement of Assets & Liabilities and Cash Flow Statement for financial year ended 31<sup>st</sup> March 2026;
- 2) Independent Auditors’ Report on Financial Results for the half and year ended 31<sup>st</sup> March, 2026, duly issued by the statutory auditor of the Company;
- 3) Declaration that the report of Auditor is with unmodified opinion with respect to Audited Financial Results for the half and year ended 31<sup>st</sup> March, 2026.

***OTHER MATTERS***

- 4) Noting of Internal Audit Report provided by the Internal Auditor of the Company, M/s M. Dutta & Associates.
- 5) Noting of Related Party Transaction(s) for the half year ended 31<sup>st</sup> March 2026.
- 6) Noting of CEO/CFO Certificate Under Regulation 17(8) of the Listing Regulations.

**NEPHRO CARE INDIA LIMITED**

*CIN: L85100WB2014PLC202429*

Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake,  
Bidhan Nagar, Sai Complex, North 24 Parganas, Kolkata – 700106.

Web: <https://www.nephrocareindia.com/>

[cs@nephrocareindia.com](mailto:cs@nephrocareindia.com) | Mobile No. 9004551166

- 7) Approval for appointment of M/s M. Dutta & Associates (Firm Registration No. 330317E)  
Chartered Accountants, as the Internal Auditor of the Company for the financial year 2026-27

The Board meeting commenced at 04:00 P.M and concluded at 6:50 P.M (IST).

The above announcements are also being made available on the website of the Company at  
[www.nephrocareindia.com](http://www.nephrocareindia.com).

Thanking you,

Yours Faithfully,

**For Nephro Care India Limited**

**Sougata Sengupta**  
**Company Secretary & Compliance Officer**



*K. K. Chanani & Associates*

**Chartered Accountants**

An ISO 9001:2008 Certified Firm, Certificate No.: 221010128008

Head Office: 5/1 Clive Row, 3<sup>rd</sup> Floor, Room No.78, Kolkata-700001

Branches: Bangalore, Chandigarh, Guwahati, Jaipur, Mumbai, New Delhi,  
Patna, Raipur and Nashik.

Contact: Dial: +91 9830044507, +9133- 22130296

Email: [kkca@kkca.net](mailto:kkca@kkca.net).

**Independent Auditor's Report on Audited Standalone Financial Results of Nephro Care India Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors of  
Nephro Care India Limited  
(formerly called Nephro Care India Private Limited)  
CIN: L85100WB2014PLC202429

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone financial results of **Nephro Care India Limited** ("the Company") for the year ended **31<sup>st</sup> March, 2026**, and the standalone assets and liabilities, the standalone statement of cash flows and the standalone segment reporting for the year ended on that date, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard and;
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India, of its profit and other financial information of the Company for the year ended **31<sup>st</sup> March, 2026** and the standalone assets and liabilities and the standalone statement of cash flows and the standalone segment reporting as at and for the year ended on that date



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs), specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Results' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

## **Emphasis of Matter**

We draw attention to the following matters in the Notes to the financial statements which describe the uncertainty related to the outcome: -

- a) During the year ended 31 March 2026, the company has written off Goods and Service Tax Receivable amounting to Rs 86.88 lacs of prior years.
  
- b) Goods and Service Tax credit amounting to Rs 247.87 lacs standing in the books as on 31 March 2026, but in Cash and Credit Ledger in GST portal is Rs NIL as on date, are subject to reconciliation and adjustments in the books on and after such reconciliation.

Our opinion is not modified in respect of the above matters

## **Management's Responsibilities for the Standalone Financial Results**

These Standalone financial results have been prepared on the basis of the standalone annual financial statements for the year ended 31<sup>st</sup> March, 2026. The Company's Board of Directors is responsible for the preparation and presentation of these standalone financial results that gives a true and fair view of its profit of the Company and other financial information and the standalone statement of assets and liabilities and standalone statement of cash flows and the standalone segment reporting in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in for the India and in compliance with Regulation 33 of the Listing Regulations.



This responsibility also includes the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

### **Auditor's Responsibility for the Audit of the Standalone Financial Statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Boards of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material



uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.


Materiality is the magnitude of misstatement in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide, those charged with governance, with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

The figures for the quarter ended 31<sup>st</sup> March 2026 and the corresponding quarter ended in the previous year as reported in the Statement are the balancing figures in respect of the full figures in respect of the full financial year ended 31<sup>st</sup> March, 2026 and the published unaudited year to date figures up to the third quarter of the current year. Also, the figures upto the end of the third quarter had only been reviewed by us as required under Listing Regulations.

  
**Krishna Kumar Chanani**  
Partner, K K Chanani & Associates  
Chartered Accountants  
Membership No. 056045  
FRN No. 322232E  
UDIN No. 26056045SNCWQI2257



Kolkata, the 27th May, 2026

Nephro Care India Limited

(Formerly called Nephro Care India Private Limited)

Registered Office:-Flat No-1JC-18, 5th Floor Sec-III, Saltlake, Kolkata, Bidhan Nagar Sai Complex, North 24 Parganas, Saltlake, West Bengal, India, 700098

Telephone No +918069841500:- Email id:- pratim.sengupta@gmail.com, website:- https://www.nephrocareindia.com

CIN:L85100WB2014PLC202429

Standalone Statement of Audited Financial Results for the Quarter and Year Ended 31 March 2026

(All amounts in ₹ lacs, unless otherwise stated)

	Quarter ended 31 March 2026 Audited	Quarter ended 31 December 2025 Unaudited	Half Year ended 31 March 2025 Audited	Year ended 31 March 2026 Audited	Year ended 31 March 2025 Audited
Revenue from operations	2,674.63	2,266.22	2,834.18	8,873.48	4,603.11
Other income	83.11	7.99	105.77	154.75	152.69
<b>Total Income</b>	<b>2,757.74</b>	<b>2,274.21</b>	<b>2,939.95</b>	<b>9,028.23</b>	<b>4,755.80</b>
<b>Expenses</b>	<b>16.37</b>	<b>(27.19)</b>	<b>(14.73)</b>	<b>(106.21)</b>	<b>(87.40)</b>
Changes in inventory of pharmacy, drugs and consumables	831.67	794.34	826.94	2,744.03	1,393.49
Purchases of pharmacy, drugs and consumables	412.50	384.73	535.59	1,483.00	759.14
Employee Benefit Expenses	(0.61)	3.37	4.97	15.87	11.01
Finance Cost	156.17	140.18	201.10	507.40	246.01
Depreciation and Amortisation	1,211.84	922.67	1,203.60	3,920.32	1,950.62
Other expenses	2,627.94	2,218.10	2,757.47	8,564.41	4,272.87
<b>Total expenses</b>	<b>129.80</b>	<b>56.11</b>	<b>182.48</b>	<b>463.82</b>	<b>482.93</b>
<b>Profit/(loss) before tax</b>	<b>29.37</b>	<b>14.02</b>	<b>37.11</b>	<b>126.92</b>	<b>119.04</b>
Tax expense	41.66	20.38	17.93	135.33	98.00
Current tax	-	-	(8.00)	-	(8.00)
Less: Mat Credit Entitlement	8.00	-	(9.65)	8.00	(9.65)
Tax Expenses of prior years	(20.29)	(6.36)	36.83	(16.41)	38.69
Deferred Tax	29.37	14.02	37.11	126.92	119.04
<b>Profit/(loss) for the period/year</b>	<b>100.43</b>	<b>42.09</b>	<b>145.37</b>	<b>336.89</b>	<b>363.89</b>
<b>Paid up equity share capital (face value Rs 10/- per share)</b>	<b>1,648.64</b>	<b>1,648.64</b>	<b>1,648.64</b>	<b>1,648.64</b>	<b>1,648.64</b>
<b>Reserve &amp; Surplus</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,036.71</b>	<b>3,699.81</b>
<b>Earnings per equity share (not annualised)</b>	<b>0.61</b>	<b>0.26</b>	<b>0.95</b>	<b>2.04</b>	<b>2.38</b>
<b>Basic and diluted</b>	<b>0.61</b>	<b>0.26</b>	<b>0.95</b>	<b>2.04</b>	<b>2.38</b>

Note:-

- The Audited standalone financial results of the company for the quarter and year ended 31 March 2026, have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on May 27, 2026. The Statutory Auditor of the company has issued unmodified opinion thereon.
- The above financial results have been prepared in accordance with and comply in all materials with the Accounting Standards (IGAAP) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of Securities and Exchange Board of India (Listing and Obligations and Disclosure Requirements) Regulations 2015, as amended
- The compliance of IND-AS is not applicable as company is listed on SME Platform on NSE Emerge
- There are no exceptional items during the period under review
- The company was listed on SME Platform on NSE Emerge on 5th July, 2024.
- The quarter ended on 31 December 2025, is the first period after listing on NSE Emerge on dated 05th July 2024 that company has voluntarily adopted reporting of the periods. Hence the financials for the quarter ended on 31 March 2025 is not provided instead of that half year ended figures from 1st October 2024 to 31st March 2025 has been provided
- Figures of the last quarter ended 31st Mar 2026 are the balancing figure between the audited figures for the full financial year and the published year to date reviewed figures upto the third quarter of the financial year.
- Figures for the previous year have been regrouped and reclassified to conform to classification of the current period wherever necessary

For and on behalf of the Board of Directors of  
Nephro Care India Limited



Pratim Sengupta

Pratim Sengupta  
Managing  
Director  
(DIN: 03501703)

Soumitra Sengupta  
(Company Secretary)  
(M.N:-A17680)

Tapas Saha

Tapas Saha  
(Chief Financial Officer)  
(PAN:BNSP8900F)

Place: Kolkata

Date: 27th Day of May 2026



Audited Standalone Statement wise Revenue, Results, Assets and Liabilities for the Quarter and Year Ended 31 March 2026  
(All amounts in ₹ Lakhs, unless otherwise stated)

Sl. No	Particulars	Quarter ended	Quarter Ended	Half Year Ended	Year ended	Year Ended
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		Audited	Unaudited	Audited	Audited	Audited
<b>1</b>	<b>Segment Revenue [Net Sales/Income]</b>					
	Income from IPD Services	1,374.47	1,063.39	972.76	4,330.48	1,075.06
	Income from OPD Services	688.69	639.58	1,250.62	2,519.18	2,382.60
	Income from sale of medicines from pharmacy	611.48	563.25	616.36	2,036.30	1,155.15
		<b>2,674.64</b>	<b>2,266.22</b>	<b>2,839.74</b>	<b>8,885.96</b>	<b>4,612.81</b>
	Less: Discount	-	-	5.56	12.47	9.70
	<b>Net Sale</b>	<b>2,674.64</b>	<b>2,266.22</b>	<b>2,834.18</b>	<b>8,873.49</b>	<b>4,603.11</b>
	Add: Profit on Sale of Investment	-	1.59	80.31	44.47	108.01
	Add: Interest Income	2.76	2.67	8.22	10.75	15.54
	Add: Technician Charges for Dialysis	-	-	0.30	1.10	1.84
	Add: Dialysis machine Rental charges	5.93	3.18	6.66	18.31	16.91
	Add: Others	74.41	0.55	10.28	80.10	10.39
	<b>Net Sales/Income from Operations</b>	<b>2,757.74</b>	<b>2,274.21</b>	<b>2,939.95</b>	<b>9,028.23</b>	<b>4,755.80</b>
	<b>Inter-Segment Sales</b>					
	Income from sale of medicines from pharmacy	257.08	191.04	21.35	906.78	21.35
<b>2</b>	<b>Information about Segment Profits:</b>					
	<b>Incomes after segment specific expenses:</b>					
	IPD Services	1,075.19	774.11	763.61	3,271.18	850.94
	OPD Services	556.26	476.47	1,202.74	2,118.53	2,328.10
	Sale of medicines from pharmacy	176.65	52.90	55.61	461.84	119.98
		<b>1,808.10</b>	<b>1,303.48</b>	<b>2,021.97</b>	<b>5,851.55</b>	<b>3,297.02</b>
	<b>Add: Other incomes</b>	83.11	7.99	105.77	154.75	152.69
	<b>Less: Unallocable expenses</b>					
	Employee Benefit Expenses	412.50	384.73	535.59	1,483.00	759.14
	Finance Cost	(0.61)	3.37	4.97	15.87	11.01
	Depreciation and Amortisation	156.17	140.18	201.10	507.40	246.01
	Other expenses	1,193.35	727.08	1,203.60	3,536.21	1,950.62
	<b>Profit/Loss before tax</b>	<b>129.80</b>	<b>56.11</b>	<b>182.48</b>	<b>463.83</b>	<b>482.93</b>
	Less: Taxes	29.37	14.02	37.11	126.94	119.04
	<b>Profit/Loss after tax</b>	<b>100.43</b>	<b>42.09</b>	<b>145.37</b>	<b>336.89</b>	<b>363.89</b>
<b>3</b>	<b>Information about segment assets &amp; liabilities</b>					
	<b>Segment Assets:</b>					
	IPD Services	3,247.03	2,422.21	3,142.63	3,247.03	3,142.63
	OPD Services	449.88	339.69	837.11	449.88	837.11
	Pharmacy	659.56	480.50	414.50	659.56	414.50
	Others	2,910.46	3,673.98	2,434.21	2,910.46	2,434.21
	<b>Total Assets</b>	<b>7,266.93</b>	<b>6,916.38</b>	<b>6,828.45</b>	<b>7,266.93</b>	<b>6,828.45</b>
	<b>Segment Liabilities:</b>					
	IPD Services	261.07	152.59	502.71	261.07	502.71
	OPD Services	118.98	113.24	255.67	118.98	255.67
	Pharmacy	687.21	598.67	383.59	687.21	383.59
	Others	514.32	429.02	338.03	514.32	338.03
	<b>Total Liabilities</b>	<b>1,581.58</b>	<b>1,293.52</b>	<b>1,480.00</b>	<b>1,581.58</b>	<b>1,480.00</b>

Note:-  
The quarter ended on 31 December 2025, is the first period after listing on NSE Emerge on dated 05th July 2024 that company has voluntarily adopted reporting of the periods. Hence the financials for the quarter ended on 31 March 2025 is not provided instead of that half year ended figures from 1st October 2024 to 31st March 2025 has been provided

Place: Kolkata  
Date: 27th Day of May 2026



*Pratim Sengupta*  
Pratim Sengupta  
Managing Director  
(DIN: 03501703)


*Sougata Sengupta*  
Sougata Sengupta  
(Company Secretary  
(M.N.-A17880))

*Tapas Saha*  
Tapas Saha  
(Chief Financial Officer)  
(PAN:BNSPS8900F)

Nephro Care India Limited  
(Formerly called Nephro Care India Private Limited)  
CIN:L85100WB2014PLC202429  
Standalone Statement of Assets and Liabilities as at 31 March 2026  
(All amounts in ₹ Lakhs , unless otherwise stated)

	As at 31 March 2026 <u>Audited</u>	As at 31 March 2025 <u>Audited</u>
<b>Equity and liabilities</b>		
<b>Shareholders' funds</b>		
Share capital	1,648.64	1,648.64
Reserves and surplus	4,036.71	3,699.81
	<u>5,685.35</u>	<u>5,348.45</u>
<b>Non-Current liabilities</b>		
Deferred Tax Liability (net)	13.81	30.22
Long-term provisions	40.50	18.64
Other Long Term Liabilities	-	28.02
	<u>54.31</u>	<u>76.88</u>
<b>Current liabilities</b>		
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	42.96	23.72
- total outstanding dues of creditors other than micro and small enterprises	627.54	359.87
Other current liabilities	621.64	921.37
Short-term provisions	235.13	98.16
	<u>1,527.27</u>	<u>1,403.12</u>
<b>Total</b>	<u><u>7,266.93</u></u>	<u><u>6,828.45</u></u>
<b>Assets</b>		
<b>Non-Current Assets</b>		
<b>Property, Plant and Equipment and Intangible Assets</b>		
(i) Property, Plant and Equipment	3,401.08	3,148.48
(ii) Capital work-in-progress	42.56	59.37
(iii) Intangible Assets under development	10.89	1.48
Non-current investments	179.78	258.43
Long term loans and advances	169.41	349.76
Other non-current assets	394.86	187.32
	<u>4,198.58</u>	<u>4,004.84</u>
<b>Current assets</b>		
Current Investments	1,001.58	1,600.00
Inventories	228.81	122.60
Trade Receivables	604.27	322.58
Cash and cash equivalents	638.57	465.83
Short term loans and advances	3.84	5.11
Other current assets	591.28	307.49
	<u>3,068.35</u>	<u>2,823.61</u>
<b>Total</b>	<u><u>7,266.93</u></u>	<u><u>6,828.45</u></u>

For and on behalf of the Board of Directors of  
Nephro Care India Limited



*Pratim Sengupta*  
Pratim Sengupta  
Managing Director  
(DIN: 03501103)

*Sougata Sengupta*  
Sougata Sengupta  
(Company Secretary)  
(M.N.-A 17680)

*Tapas Saha*  
Tapas Saha  
(Chief Financial Officer)  
(PAN:BNSPS8900F)

Place: Kolkata  
Date: 27th Day of May 2026

**Nephro Care India Limited**  
 (Formerly called Nephro Care India Private Limited)  
 CIN:L85100WB2014PLC202429  
 Standalone Statement of Cash Flow for the year ended 31 March 2026  
 (All amounts in ₹ Lakhs , unless otherwise stated)

	Year Ended 31 March 2026 Audited	Year ended 31 March 2025 Audited
<b>A. Cash flow from operating activities :</b>		
Profit before tax	463.82	482.93
Adjustment for :		
Depreciation	507.40	246.01
Interest Income from Fixed Deposit	(10.75)	(15.54)
Sundry Balance Written Off	(67.64)	(7.88)
GST Written off	86.88	
Profit from sale of investments	(44.47)	(108.01)
<b>Operating profit before working capital changes</b>	<b>935.24</b>	<b>597.51</b>
<b>Adjustments for changes in working capital:</b>		
<b>(Increase) / decrease in assets:</b>		
Inventories	(106.21)	(87.40)
Trade Receivables	(281.68)	(307.17)
Other current assets	(201.84)	(188.27)
Short-term loans and advances	1.27	4.85
Long-term loans and advances	180.35	(43.99)
Other non-current assets	(207.54)	(54.68)
<b>Increase / (decrease) in liabilities:</b>		
Trade Payables	286.91	196.17
Long-term provisions	21.85	10.89
Short-term provisions	1.63	(0.17)
Other current liabilities	(232.20)	702.11
<b>Cash generated from operations</b>	<b>397.78</b>	<b>829.87</b>
Income taxes paid (net of refunds)	(176.71)	(106.31)
<b>Net cash generated from operating activities (A)</b>	<b>221.07</b>	<b>723.56</b>
<b>B. Cash flow from investing activities</b>		
Purchase of Property, Plant and Equipment	(769.41)	(2,920.98)
Capital work-in -progress	(11.21)	(59.37)
Proceeds from Fixed Deposits	244.00	2,495.00
Investment in Fixed Deposits	(158.80)	(2,753.43)
Redemption of Mutual Fund	1,842.89	4,867.03
Investment in Mutual Funds	(1,200.00)	(5,600.00)
Investment in Subsidiary	(5.10)	15.54
Interest Income from Fixed Deposits	9.31	
<b>Net cash used in investing activities (B)</b>	<b>(48.32)</b>	<b>(3,956.22)</b>
<b>C. Cash flow from financing activities</b>		
Proceeds/(Repayment) from Borrowings	-	0.00
Government Grant Received	-	28.02
Increase in Share Capital	-	458.40
Securities Premium Received (Net)	-	3,109.55
<b>Net cash used in financing activities (C)</b>	<b>-</b>	<b>3,595.97</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>172.74</b>	<b>336.77</b>
Cash and cash equivalents as at the beginning of the year	465.83	129.06
Cash and cash equivalents as at the end of the year	<b>638.57</b>	<b>465.83</b>
<b>Note:</b>		
Cash and bank balances	638.57	465.83
Less: Other bank balances		
<b>Cash and cash equivalents</b>	<b>638.57</b>	<b>465.83</b>

The standalone statement of cashflow has been prepared under the indirect method as set out in Accounting Standard 3 on Cash Flow Statement as specified under Section 133 of the Companies Act 2013 read with Companies (Accounting Standards) Rules, 2021



For and on behalf of the Board of Directors of  
 Nephro Care India Limited

*Pratim Sengupta*  
 Pratim Sengupta  
 Managing Director  
 (DIN: 03501703)

*Tapas Saha*  
 Tapas Saha  
 (Chief Financial Officer)  
 (PAN: BNSPS8900F)

*Sougata Sengupta*  
 Sougata Sengupta  
 (Company Secretary)  
 (M.N:-A17680)

Place: Kolkata  
 Date: 27th Day of May 2026



*K. K. Chanani & Associates*

**Chartered Accountants**

An ISO 9001:2008 Certified Firm, Certificate No.: 221010128008

Head Office: 5/1 Clive Row, 3<sup>rd</sup> Floor, Room No.78, Kolkata-700001

Branches: Bangalore, Chandigarh, Guwahati, Jaipur, Mumbai, New Delhi,  
Patna, Raipur and Nashik.

Contact: Dial: +91 9830044507, +9133- 22130296

Email: [kkca@kkca.net](mailto:kkca@kkca.net).

**Independent Auditor's Report on the Consolidated Financial Results Nephro Care India Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors of  
Nephro Care India Limited  
(formerly called Nephro Care India Private Limited)  
CIN: L85100WB2014PLC202429

**Report on the audit of the Consolidated Financial Results**

**Opinion**

We have audited the accompanying consolidated annual financial results of **Nephro Care India Limited** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary referred to as "Group") for the year ended **31<sup>st</sup> March, 2026** and the consolidated statement of assets and liabilities and the consolidated statement of cash flows and the consolidated statement of segment reporting as at and for the year ended on that date, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements/financial information of this subsidiary the aforesaid consolidated financial results for the year ended 31 March 2026

- i. includes the result of the entity **Vivacity Multiple Ventures Private Limited**
- ii. are presented in accordance with the requirements of the Listing Regulations in this regard and;
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act , 2013 and other accounting principles generally accepted in India, of its profit and other financial information of the



Group for the year ended 31<sup>st</sup> March, 2026 and the consolidated assets and liabilities and the consolidated statement of cash flows and the consolidated statement of segment reporting as at and for the year ended on that date

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs), specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Consolidated Financial Results' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us and the other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters

### **Emphasis of Matter**

We draw attention to the following matters in the Notes to the financial statements of the Holding Company which describe the uncertainty related to the outcome: -

- a) During the year ended 31 March 2026, the company has written off Goods and Service Tax Receivable amounting to Rs 86.88 lacs of prior years.
- b) Goods and Service Tax credit amounting to Rs 247.87 lacs standing in the books as on 31 March 2026, but in Cash and Credit Ledger in GST portal is Rs NIL as on date , are subject to reconciliation and adjustments in the books on and after such reconciliation.

Our opinion is not modified in respect of the above matters

### **Management's Responsibilities for the Consolidated Financial Results**

The consolidated financial results have been prepared on the basis of the consolidated annual financial statements for the year ended 31<sup>st</sup> March, 2026. The Holding Company's Board of Directors are responsible for the preparation and presentation of the consolidated financial results that gives a true and fair view of its profit of the Company and other



financial information of the Group, the consolidated statement of assets and liabilities and the consolidated statement of cash flows and the consolidated statement of segment reporting in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in for the India and in compliance with Regulation 33 of the Listing Regulations.

This respective Management and the Board of the Directors of the Companies included in Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial results, the respective Management and Board of Directors of the Companies included in Group are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are also responsible for overseeing the company's financial reporting process of each company.

#### **Auditor's Responsibility for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of



expressing an opinion on the effectiveness of the Company's internal control. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Boards of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial results represents the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatement in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide, those charged with governance, with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matter**


The accompanying statement includes the audited financial result /statement and other financial information of its subsidiary, whose result/statement includes assets of Rs. 10.26 lacs, revenues NIL, profit after tax NIL for the quarter and year ended 31 March 2026 as on that date respectively, and net cash outflows Rs. NIL lacs for the year ended March 31,2026 as considered in the Statement which has been audited by the respective independent auditor

The independent auditor's report on the financial statement /financial results of the entity have been furnished to us by the Management and our opinion on the Statement in so far



as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.

The figures for the quarter ended 31<sup>st</sup> March 2026 and the corresponding quarter ended in the previous year as reported in the Statement are the balancing figures in respect of the full figures in respect of the full financial year ended 31<sup>st</sup> March, 2026 and the published unaudited year to date figures up to the third quarter of the current year. Also, the figures upto the end of the third quarter had only been reviewed by us as required under Listing Regulations.

  
**Krishna Kumar Chanani**  
Partner, KK Chanani & Associates  
Chartered Accountants  
Membership No. 056045  
FRN No. 322232E  
UDIN No. 26056045HNWLKY6337



Kolkata, the 27<sup>th</sup> May, 2026

Nephro Care India Limited  
 (Formerly called Nephro Care India Private Limited)  
 Registered Office: Flat No-1JC-10, 5th Floor Sec-III, Saltlake, Kolkata, Bidhan Nagar Sai Complex,  
 North 24 Parganas, Saltlake, West Bengal, India, 700098  
 Telephone No +918069841500 - Email Id - pratim.sengupta@gmail.com, website - https://www.nephrocareindia.com  
 CIN: L05100WB2014PLC202429  
 Consolidated Statement of Audited Financial Results for the Quarter and Year Ended 31 March 2026  
 (All amounts in ₹ Lacs unless otherwise stated)

	Quarter ended 31 March 2026 Audited	Year ended 31 March 2025 Audited
Revenue from operations	2,674.63	8,873.48
Other income	83.11	154.75
<b>Total Income</b>	<b>2,757.74</b>	<b>9,028.23</b>
<b>Expenses</b>		
Changes in inventory of pharmacy, drugs and consumables	15.37	(100.21)
Purchases of pharmacy, drugs and consumables	831.67	2,744.03
Employee Benefit Expenses	412.50	1,443.00
Finance Cost	(0.61)	15.87
Depreciation and Amortisation	156.17	507.40
Other expenses	1,211.84	3,920.32
<b>Total expenses</b>	<b>2,627.94</b>	<b>8,564.41</b>
<b>Profit/(loss) before tax</b>	<b>129.80</b>	<b>463.82</b>
<b>Tax expense</b>		
Current tax	41.66	135.33
Tax Expenses of prior years	8.00	8.00
Deferred Tax	(20.29)	(16.41)
	<b>29.37</b>	<b>126.92</b>
<b>Profit/(loss) for the period/year</b>	<b>100.43</b>	<b>336.89</b>
<b>Profit/(Loss) for the year-attributable to owners of the parent</b>	<b>100.43</b>	<b>336.89</b>
<b>Profit/(Loss) for the year -attributable to minority interest</b>	<b>-</b>	<b>-</b>
<b>Paid up equity share capital (face value Rs 10/- per share)</b>	<b>1,648.64</b>	<b>1,648.64</b>
<b>Reserve &amp; Surplus</b>	<b>-</b>	<b>4,036.71</b>
<b>Earnings per equity share (not annualised)</b>		
Basic and diluted	0.61	2.04

**Note-**

- 1) The Consolidated Audited financial results of the company for the quarter and year ended ended 31 March 2026, have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on May 27, 2026. The Statutory Auditor of the company has issued
- 2) The above financial results have been prepared in accordance with and comply in all materials with the Accounting Standards (IGAAP) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of Securities and Exchange Board of India (Listing and Obligations and Disclosure Requirements) Regulations 2015, as amended
- 3) The compliance of IND-AS is not applicable as company is listed on SME Platform on NSE Emerge
- 4) There are no exceptional items during the period under review
- 5) The company was listed on SME Platform on NSE Emerge on 5th July, 2024.
- 6) The company has incorporated a subsidiary entity in the name of "VIVACITY MULTIPLE VENTURES PRIVATE LIMITED" on 18th December, 2025. The company has only completed the legal formalities regarding the incorporation of the aforesaid subsidiary and is yet to commence
- 7) This is the first quarter of consolidation of accounts hence previous year figures not provided

For and on behalf of the Board of Directors of  
Nephro Care India Limited



*Pratim Sengupta*  
 Pratim Sengupta  
 Managing Director  
 (DIN: 03501703)  
*Tapas Saha*  
 Tapas Saha  
 (Chief Financial Officer)  
 (PAN: BNSP8900F)

*Sougata Sengupta*  
 Sougata Sengupta  
 (Company Secretary)  
 (M.N. -A17680)

Place: Kolkata  
 Date: 27th Day of May 2026

**Nephro Care India Limited**  
 (Formerly called Nephro Care India Private Limited)  
 CIN:L85100WB2014PLC202429  
**Consolidated Statement of Assets and Liabilities as at 31 March 2026**  
 (All amounts in ₹ Lakhs , unless otherwise stated)

	As at 31 March 2026 <u>Audited</u>
<b>Equity and liabilities</b>	
<b>Shareholders' funds</b>	
Share capital	1,648.64
Reserves and surplus	4,036.71
<b>Total of equity (for shareholders of Parent)</b>	<b>5,685.35</b>
Minority Interest	4.90
	<u>5,690.25</u>
<b>Non-Current liabilities</b>	
Deferred Tax Liability (net)	13.81
Long-term provisions	40.50
	<u>54.31</u>
<b>Current liabilities</b>	
Trade Payables	
- total outstanding dues of micro enterprises and small enterprises	42.96
- total outstanding dues of creditors other than micro and small enterprises	627.54
Other current liabilities	621.90
Short-term provisions	235.13
	<u>1,527.53</u>
	<u>7,272.09</u>
<b>Total</b>	
<b>Assets</b>	
<b>Non-Current Assets</b>	
<b>Property, Plant and Equipment and Intangible Assets</b>	
(i) Property, Plant and Equipment	3,401.08
(ii) Capital work-in-progress	42.56
(iii) Intangible Assets under development	10.89
Non-current investments	174.68
Long term loans and advances	169.41
Other non-current assets	394.86
	<u>4,193.48</u>
<b>Current assets</b>	
Current Investments	1,001.58
Inventories	228.81
Trade Receivables	604.27
Cash and cash equivalents	648.57
Short term loans and advances	3.84
Other current assets	591.54
	<u>3,078.61</u>
	<u>7,272.09</u>
<b>Total</b>	

Note: This is the first year of consolidation of accounts hence previous year figures not provided

For and on behalf of the Board of Directors of  
**Nephro Care India Limited**



*Pratim Sengupta*  
**Pratim Sengupta**  
 Managing Director  
 (DIN: 03501109)

*Tapas Saha*

**Tapas Saha**  
 (Chief Financial Officer)  
 (PAN:BNSP8900F)

*Sougata Sengupta*  
**Sougata Sengupta**  
 (Company Secretary)  
 (M.N:-A17680)

Place: Kolkata  
 Date: 27th Day of May 2026



	Year Ended 31 March 2026 Audited
<b>A. Cash flow from operating activities :</b>	
Profit before tax	463.82
Adjustment for :	
Depreciation	507.40
Interest Income from Fixed Deposit	(10.75)
Sundry Balance Written Off	(67.64)
GST Written off	86.88
Profit from sale of investments	(44.47)
<b>Operating profit before working capital changes</b>	<b>935.24</b>
<b>Adjustments for changes in working capital:</b>	
<b>(Increase) / decrease in assets:</b>	
Inventories	(106.21)
Trade Receivables	(281.68)
Other current assets	(202.10)
Short-term loans and advances	1.27
Long-term loans and advances	180.35
Other non-current assets	(207.54)
<b>Increase / (decrease) in liabilities:</b>	
Trade Payables	286.91
Long-term provisions	21.85
Short-term provisions	1.63
Other current liabilities	(231.94)
<b>Cash generated from operations</b>	<b>397.78</b>
Income taxes paid (net of refunds)	(176.71)
<b>Net cash generated from operating activities</b>	<b>221.07</b>
<b>B. Cash flow from investing activities</b>	
Purchase of Property, Plant and Equipment	(769.41)
Capital work-in -progress	(11.21)
Proceeds from Fixed Deposits	244.00
Investment in Fixed Deposits	(158.80)
Redemption of Mutual Fund	1,842.89
Investment in Mutual Funds	(1,200.00)
Interest Income from Fixed Deposits	9.31
<b>Net cash used in investing activities</b>	<b>(43.22)</b>
<b>C. Cash flow from financing activities</b>	
Share Capital of Monority Interest	4.90
<b>Net cash used in financing activities</b>	<b>4.90</b>
<b>Net increase in cash and cash equivalents</b>	<b>182.74</b>
Cash and cash equivalents as at the beginning of the year	465.83
Cash and cash equivalents as at the end of the year	<b>648.57</b>
<b>Note:</b>	
Cash and bank balances	648.57
Less: Other bank balances	
<b>Cash and cash equivalents</b>	<b>648.57</b>

The consolidated statement of cashflow has been prepared under the indirect method as set out in Accounting Standard 3 on Cash Flow Statement as specified under Section 133 of the Companies Act 2013 read with Companies (Accounting Standards) Rules, 2021



Place: Kolkata  
Date: 27th Day of May 2026

For and on behalf of the Board of Directors of  
Nephro Care India Limited

*Pratim Sengupta*  
Pratim Sengupta  
Managing Director  
(DIN: 03501103)

*Soumitra Sengupta*  
Soumitra Sengupta  
(Company Secretary)  
(M.N:-A17680)


*Tapas Saha*  
Tapas Saha  
(Chief Financial Officer)  
(PAN:BNSPS8900F)




## Sl. No Particulars

Sl. No Particulars	Quarter ended	Year ended
	31 March 2026	31 March 2026
	Audited	Audited
<b>1 Segment Revenue [Net Sales/Income]</b>		
Income from IPD Services		
Income from OPD Services	1,374.47	4,330.48
Income from sale of medicines from pharmacy	688.69	2,519.18
	611.48	2,036.30
	<u>2,674.64</u>	<u>8,885.96</u>
Less: Discount	-	12.47
<b>Net Sale</b>	<u>2,674.64</u>	<u>8,873.49</u>
Add: Profit on Sale of Investment	-	44.47
Add: Interest Income	2.76	10.75
Add: Technician Charges for Dialysis	-	1.10
Add: Dialysis machine Rental charges	5.93	18.31
Add: Others	74.41	80.10
<b>Net Sales/Income from Operations</b>	<u>2,757.74</u>	<u>9,028.23</u>
<b>Inter-Segment Sales</b>		
Income from sale of medicines from pharmacy	257.08	906.78
<b>2 Information about Segment Profits:</b>		
<b>Incomes after segment specific expenses:</b>		
IPD Services	1,075.19	3,271.18
OPD Services	556.26	2,118.53
Sale of medicines from pharmacy	176.65	461.84
	<u>1,808.10</u>	<u>5,851.55</u>
Add: Other incomes	83.11	154.75
Less: Unallocable expenses		
Employee Benefit Expenses	412.50	1,483.00
Finance Cost	(0.61)	15.87
Depreciation and Amortisation	156.17	507.40
Other expenses	1,193.35	3,536.22
<b>Profit/Loss before tax</b>	<u>129.80</u>	<u>463.82</u>
Less: Taxes	29.37	126.93
<b>Profit/Loss after tax</b>	<u>100.43</u>	<u>336.89</u>
<b>3 Information about segment assets &amp; liabilities</b>		
<b>Segment Assets:</b>		
IPD Services	3,247.03	3,247.03
OPD Services	449.88	449.88
Pharmacy	659.56	659.56
Others	2,915.62	2,915.62
<b>Total Assets</b>	<u>7,272.09</u>	<u>7,272.09</u>
<b>Segment Liabilities:</b>		
IPD Services	261.07	261.07
OPD Services	118.98	118.98
Pharmacy	687.21	687.21
Others	514.58	514.58
<b>Total Liabilities</b>	<u>1,581.84</u>	<u>1,581.84</u>

Note -

This is the first year of consolidation of accounts hence previous year figures not provided




Pratim Sengupta  
Managing Director  
(DIN: 03501703)

Sougata Sengupta  
(Company Secretary)  
(M.N.-A17680)

Tapas Saha  
(Chief Financial Officer)  
(PAN:BNSPS8900F)

Place: Kolkata

Date 27th Day of May 2026

**NEPHRO CARE INDIA LIMITED**

CIN: L85100WB2014PLC202429

Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake,  
Bidhan Nagar, Sai Complex, North 24 Parganas, Kolkata – 700106.

Web: <https://www.nephrocareindia.com/>

es@nephrocareindia.com | Mobile No. 9004551166

**Date: 27/05/2026**

To,  
**The Manager - Listing Department**  
**National Stock Exchange of India Limited,**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051

**Symbol - NEPHROCARE**

**Sub: Declaration pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.**

Dear Sir/Madam,


We, Nephro Care India Limited having its registered office at Flat No-1, JC-18, 5th Floor Sec-III, Saltlake, Bidhan Nagar, Sai Complex, North 24 Parganas, Kolkata – 700106, do hereby declare and confirm that the Audit report issued by M/S K K Chanani & Associates, Chartered Accountants (Firm Registration No. 322232E), Statutory Auditors of the Company on the Annual Audited Financial Results for the Financial year ended 31<sup>st</sup> March, 2026 is with unmodified opinion.

This declaration is being made pursuant to the regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this declaration on record.

Thanking you,

Yours Faithfully,  
For **Nephro Care India Limited**



**Dr. Pratim Sengupta**  
**Managing Director**  
**DIN:03501703**